Tyrosine Kinase Inhibitor

A tyrosine kinase inhibitor, or TKI, is a type of targeted cancer drug that blocks specific enzymes (tyrosine kinases) that tumor cells use to grow and spread. Because they aim at particular molecular signals rather than dividing cells broadly, they can differ from traditional chemotherapy in their side effects. Several have been tested in mesothelioma, though results there have so far been limited.

Origin

The first successful TKI, imatinib, was approved in 2001 for chronic myeloid leukemia and proved that blocking a single driver enzyme could control cancer. This launched a large class of targeted drugs now used across many tumor types.

Significance in Asbestos Context

For mesothelioma patients, tyrosine kinase inhibitors are mainly relevant through clinical trials and molecular testing rather than standard care, since no TKI is a frontline mesothelioma treatment. Some tumors are tested for specific molecular targets, and a matching TKI may be offered on a trial or off-label basis. Ask your oncologist whether molecular or genomic testing of your tumor has been done and whether any targeted-therapy trials fit your case. Understanding that these drugs are targeted, not a cure-all, helps set realistic expectations.

Example Sentence

Her oncologist discussed a clinical trial of a tyrosine kinase inhibitor after her tumor's molecular profile was analyzed.

Related Terms

Targeted Therapy, Immunotherapy, Chemotherapy, Clinical Trial, Genomic Testing, Mesothelioma

Notes

• Ask whether your tumor tissue has had molecular or genomic profiling, which is what identifies a possible target.
• If you consider a trial, ask about eligibility, travel, costs, and how it fits with your standard treatment.
• Keep your pathology and molecular reports together; the same tissue analysis can serve both treatment and documenting your disease.